CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVAC) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 4,850,000 shares, an increase of 19.5% from the March 15th total of 4,060,000 shares. Based on an average daily trading volume, of 812,400 shares, the short-interest ratio is currently 6.0 days. Approximately 5.2% of the company’s shares are short sold.

CureVac Trading Down 0.2 %

Shares of NASDAQ CVAC traded down $0.01 during midday trading on Tuesday, hitting $3.21. The stock had a trading volume of 98,268 shares, compared to its average volume of 805,549. The company has a fifty day moving average price of $3.07 and a 200 day moving average price of $3.17. The company has a market capitalization of $719.00 million, a price-to-earnings ratio of 5.83 and a beta of 2.48. CureVac has a 1-year low of $2.22 and a 1-year high of $5.28. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The company had revenue of $15.44 million for the quarter, compared to analyst estimates of $6.40 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. On average, analysts predict that CureVac will post 0.72 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CVAC. Two Sigma Advisers LP acquired a new stake in CureVac in the fourth quarter valued at $48,000. Jump Financial LLC bought a new stake in CureVac in the fourth quarter valued at about $55,000. D. E. Shaw & Co. Inc. acquired a new position in shares of CureVac in the 4th quarter worth approximately $66,000. Barclays PLC acquired a new position in CureVac in the third quarter worth $67,000. Finally, XTX Topco Ltd grew its position in shares of CureVac by 90.2% during the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock valued at $83,000 after buying an additional 11,553 shares during the last quarter. Hedge funds and other institutional investors own 17.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a report on Friday, February 14th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.